Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Inclusion Criteria: * Histologically confirmed diagnosis of advanced solid tumours or lymphoma, except for primitive hepatocarcinoma for which radiological diagnosis only is permitted; * Advanced or metastatic disease refractory to standard curative or palliative therapy or contraindication or have refused standard therapy, * Measurable and/or evaluable disease, * Age ≥ 18 years, * ECOG performance ≤ 1 * Life expectancy ≥ 3 months, * If female, neither pregnant or lactating, * Negative pregnancy test for females at screening, preferably done within 1 week before Day 1 of treatment (not applicable to patients with bilateral oophorectomy and/or hysterectomy), * Agreeing to use appropriate medically approved contraception (physical barrier contraception is recommended) from study entry to 6 months after the last day of treatment for the patient, * Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL; calculated creatinine clearance ≥ 60mL/min (calculated according to the formula of Cockroft and Gault); total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In patients with documented liver metastases, the AST/ALT may be ≤ 3.5x ULN; prothrombin time ≤1.5x ULN, kalemia, magnesemia and phosphatemia \> LLN (Lower Limit of Normal) * Able to render informed consent and to follow protocol requirements, * Able to swallow capsules, * Able to comply with scheduled plans, laboratory tests, and other study procedures. Exclusion Criteria: * Received investigational agents or systemic anti-cancer agents within 14 days of Day 1 of treatment, or 28 days for those agents with unknown elimination half-lives, or known elimination half-lives greater than 50 hours; or 6 weeks for Mitomycine C or for nitrosourea agents, * Unresolved toxicity from previous treatment or previous investigational agents, * Patients with history of prior radiation that potentially included the heart in the field (e.g. mantle), * Cardiac exclusion criteria: * History of significant coronary artery disease or congestive heart failure that meets NYHA class III or IV, within 12 months (see Appendix D), * Significant cardiovascular dysfunction : pulmonary hypertension, right ventricular systolic dysfunction, aortic stenosis, mitral insufficiency \> grade 2 and/or Left Ventricular Ejection fraction \< 45% or \< 55% if prior exposure to anthracyclines, based on MUGA or echocardiography, * Uncontrolled hypertension (Systolic \> 150 or diastolic \>100), * Permanent and uncontrolled cardiac rhythm disorders and clinical relevant abnormalities in 12-lead ECG/Holter, such as WPW (Wolff-Parkinson-White) syndrome, QRS \> 120 msec, PR \> 220 msec, heart rate \< 50 bpm, Q wave, ST deviation, left bundle branch block, atrial fibrillation, flutter, tachysystoly. * Prolonged QTc interval \> 450 msec in men and \> 470 msec in women using Fridericia formula, * Congenital long QT syndrome, * Use of any medication associated with known QTc interval prolongation (a non-exhaustive list will be provided separately) * Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C, * Patients with uncontrolled brain metastases, * Gastrointestinal diseases or disorders that could affect drug absorption such as diarrhoea, major abdominal surgery, significant bowel obstruction and/or gastrointestinal diseases that could alter the assessment of safety, including any of the following: * Irritable bowel syndrome * Ulcerative colitis * Crohn disease * Haemorrhagic coloproctitis * Concurrent participation with any other anticancer therapy.